WO2017067530A3 - 一种治疗前列腺癌的组合、药物组合物及治疗方法 - Google Patents

一种治疗前列腺癌的组合、药物组合物及治疗方法 Download PDF

Info

Publication number
WO2017067530A3
WO2017067530A3 PCT/CN2017/073380 CN2017073380W WO2017067530A3 WO 2017067530 A3 WO2017067530 A3 WO 2017067530A3 CN 2017073380 W CN2017073380 W CN 2017073380W WO 2017067530 A3 WO2017067530 A3 WO 2017067530A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
prostate cancer
treatment method
combination
treating prostate
Prior art date
Application number
PCT/CN2017/073380
Other languages
English (en)
French (fr)
Other versions
WO2017067530A2 (zh
Inventor
戈传生
廖柏松
李文成
Original Assignee
康朴生物医药技术（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ756412A priority Critical patent/NZ756412B2/en
Priority to US16/482,549 priority patent/US20200000776A1/en
Priority to AU2017202864A priority patent/AU2017202864B2/en
Priority to JP2019543848A priority patent/JP6773915B2/ja
Priority to RU2019127449A priority patent/RU2733950C1/ru
Priority to EP17718469.4A priority patent/EP3581182B1/en
Priority to PCT/CN2017/073380 priority patent/WO2017067530A2/zh
Priority to CA3053805A priority patent/CA3053805C/en
Application filed by 康朴生物医药技术（上海）有限公司 filed Critical 康朴生物医药技术（上海）有限公司
Priority to PL17718469T priority patent/PL3581182T3/pl
Priority to ES17718469T priority patent/ES2899372T3/es
Priority to CN201780085859.9A priority patent/CN110248662B/zh
Priority to KR1020197026618A priority patent/KR102125661B1/ko
Publication of WO2017067530A2 publication Critical patent/WO2017067530A2/zh
Publication of WO2017067530A3 publication Critical patent/WO2017067530A3/zh
Priority to ZA2019/05222A priority patent/ZA201905222B/en
Priority to US17/325,468 priority patent/US20210267946A1/en
Priority to US18/404,967 priority patent/US20240139156A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了一种治疗前列腺癌的组合、药物组合物及治疗方法。本发明公开的组合包含通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种，以及雄激素受体通路调节剂。本发明的组合、其药物组合物及治疗方法能够更有效地抑制前列腺癌。
PCT/CN2017/073380 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法 WO2017067530A2 (zh)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PL17718469T PL3581182T3 (pl) 2017-02-13 2017-02-13 Kombinacja lecząca nowotwór złośliwy gruczołu krokowego, kompozycja farmaceutyczna i sposób leczenia
US16/482,549 US20200000776A1 (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
ES17718469T ES2899372T3 (es) 2017-02-13 2017-02-13 Combinación de tratamiento del cáncer de próstata, composición farmacéutica y método de tratamiento
RU2019127449A RU2733950C1 (ru) 2017-02-13 2017-02-13 Комбинация для лечения рака предстательной железы, фармацевтическая композиция и способ лечения
EP17718469.4A EP3581182B1 (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
PCT/CN2017/073380 WO2017067530A2 (zh) 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法
CA3053805A CA3053805C (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
NZ756412A NZ756412B2 (en) 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
AU2017202864A AU2017202864B2 (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
JP2019543848A JP6773915B2 (ja) 2017-02-13 2017-02-13 前立腺癌を治療する組み合わせ、薬物組成物および治療方法
CN201780085859.9A CN110248662B (zh) 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法
KR1020197026618A KR102125661B1 (ko) 2017-02-13 2017-02-13 전립선암 치료용 조합, 약학 조성물 및 치료 방법
ZA2019/05222A ZA201905222B (en) 2017-02-13 2019-08-07 Combination treating prostate cancer, pharmaceutical composition and treatment method
US17/325,468 US20210267946A1 (en) 2017-02-13 2021-05-20 Combination treating prostate cancer, pharmaceutical composition and treatment method
US18/404,967 US20240139156A1 (en) 2017-02-13 2024-01-05 Combination treating prostate cancer, pharmaceutical composition and treatment method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/073380 WO2017067530A2 (zh) 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/482,549 A-371-Of-International US20200000776A1 (en) 2017-02-13 2017-02-13 Combination treating prostate cancer, pharmaceutical composition and treatment method
US17/325,468 Continuation US20210267946A1 (en) 2017-02-13 2021-05-20 Combination treating prostate cancer, pharmaceutical composition and treatment method

Publications (2)

Publication Number Publication Date
WO2017067530A2 WO2017067530A2 (zh) 2017-04-27
WO2017067530A3 true WO2017067530A3 (zh) 2017-12-21

Family

ID=58558089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/073380 WO2017067530A2 (zh) 2017-02-13 2017-02-13 一种治疗前列腺癌的组合、药物组合物及治疗方法

Country Status (12)

Country Link
US (3) US20200000776A1 (zh)
EP (1) EP3581182B1 (zh)
JP (1) JP6773915B2 (zh)
KR (1) KR102125661B1 (zh)
CN (1) CN110248662B (zh)
AU (1) AU2017202864B2 (zh)
CA (1) CA3053805C (zh)
ES (1) ES2899372T3 (zh)
PL (1) PL3581182T3 (zh)
RU (1) RU2733950C1 (zh)
WO (1) WO2017067530A2 (zh)
ZA (1) ZA201905222B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN110049765B (zh) * 2016-12-16 2022-02-01 康朴生物医药技术（上海）有限公司 一种组合、其应用及治疗方法
KR102014478B1 (ko) 2017-05-12 2019-08-26 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2018208123A1 (ko) * 2017-05-12 2018-11-15 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
US20200197416A1 (en) * 2017-08-09 2020-06-25 Nangenex Nanotechnology Incorporated Pharmaceutical composition comprising abiraterone acetate and darulotamide
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
EP3773565A4 (en) * 2018-03-29 2021-12-15 Hinova Pharmaceuticals Inc. DEUTERCED IMIDAZOLIDINDIONE COMPOUNDS AND THEIR USES
FI3784663T3 (fi) 2018-04-23 2023-10-06 Celgene Corp Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
KR102542275B1 (ko) * 2018-05-14 2023-06-12 하이노바 파마슈티컬스 인코포레이티드 Hc-1119 제제 및 그 제조방법 및 용도
CN111514140B (zh) * 2019-02-01 2021-09-03 江苏恒瑞医药股份有限公司 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途
CN113677664A (zh) 2019-04-12 2021-11-19 C4医药公司 Ikaros和aiolos的三环降解物
KR102479869B1 (ko) 2020-06-05 2022-12-21 중앙대학교 산학협력단 당단풍나무 추출물 또는 이의 분획물을 포함하는 전립선암 예방, 치료, 또는 개선용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013087004A1 (zh) * 2011-12-14 2013-06-20 Chen Yuanwei 咪唑二酮类化合物及其用途
WO2014152833A1 (en) * 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740140D1 (de) 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8940719B2 (en) * 2006-07-03 2015-01-27 Academia Sinica Lithocholic acid analogues that inhibit sialyltransferase
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
CN102482230B (zh) * 2009-09-10 2016-01-06 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
WO2011057064A1 (en) * 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
DK2683694T3 (en) * 2011-03-10 2016-07-18 Suzhou Kintor Pharmaceuticals Inc ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF
SI2894151T1 (sl) 2012-09-04 2021-01-29 Shanghai Hengrui Pharmaceutical Co. Ltd. Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini
AU2013334102B2 (en) * 2012-10-26 2018-08-16 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor
JP6469092B2 (ja) * 2013-05-29 2019-02-13 ヒノバ ファーマシューティカルズ インコーポレイテッド イミダゾリジンジオン化合物及び薬物組成物
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
AU2015247817C1 (en) * 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
PL3214081T3 (pl) * 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
EP3357513B1 (en) * 2015-09-29 2023-10-25 Kangpu Biopharmaceuticals, Ltd. Pharmaceutical composition and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013087004A1 (zh) * 2011-12-14 2013-06-20 Chen Yuanwei 咪唑二酮类化合物及其用途
WO2014152833A1 (en) * 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PANG, RAN ET AL.: "Advances of Therapeutic Approaches for Hormone Refractory Prostate Cancer", CHINESE JOURNAL OF SURGERY , OF INTEGRATED TRADUTIONAL AND WESTERN MEDICINE, vol. 19, 28 February 2013 (2013-02-28), pages 100 - 102, XP009505371, ISSN: 1007-6948 *

Also Published As

Publication number Publication date
ZA201905222B (en) 2020-05-27
AU2017202864B2 (en) 2020-04-23
CN110248662B (zh) 2022-08-16
CA3053805A1 (en) 2017-04-27
ES2899372T3 (es) 2022-03-11
KR102125661B1 (ko) 2020-06-22
NZ756412A (en) 2021-01-29
CN110248662A (zh) 2019-09-17
JP2020506216A (ja) 2020-02-27
US20200000776A1 (en) 2020-01-02
US20240139156A1 (en) 2024-05-02
WO2017067530A2 (zh) 2017-04-27
US20210267946A1 (en) 2021-09-02
CA3053805C (en) 2020-06-30
PL3581182T3 (pl) 2022-01-17
EP3581182A2 (en) 2019-12-18
EP3581182A4 (en) 2020-02-26
KR20190111133A (ko) 2019-10-01
JP6773915B2 (ja) 2020-10-21
EP3581182B1 (en) 2021-09-29
RU2733950C1 (ru) 2020-10-08
AU2017202864A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
WO2017067530A3 (zh) 一种治疗前列腺癌的组合、药物组合物及治疗方法
NZ742001A (en) Pharmaceutical composition and application thereof comprising a benzoheterocyclic compound
JOP20190229A1 (ar) مركبات تثبط بروتين mcl-1
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
EP3895717A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12019501639A1 (en) Jaki selective inhibitors
MX2023008954A (es) Inhibidores de los receptores erbb.
EA201891578A1 (ru) Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида
EP3417853A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER CONTAINING POLYPHENOL COMPOUND AS ACTIVE INGREDIENT
PH12019550154A1 (en) Azetidine derivative
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
TN2016000491A1 (en) Carboxamide derivatives.
TN2016000489A1 (en) Carboxamide derivatives.
MX2020008498A (es) Derivados de sobetirome.
WO2019054891A3 (en) Trpv2 antagonists
WO2017165822A8 (en) Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
GB2564262A (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
ECSP18023544A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
WO2018005444A3 (en) Methods for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17718469

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3053805

Country of ref document: CA

Ref document number: 2019543848

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197026618

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017718469

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017202864

Country of ref document: AU

Date of ref document: 20170213

Kind code of ref document: A